Ascendis Pharma AS (ASND) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Ascendis Pharma AS stock (ASND) is currently trading at $220.90. Ascendis Pharma AS PS ratio (Price-to-Sales) is 18.38. Analyst consensus price target for ASND is $290.54. WallStSmart rates ASND as Sell.
- ASND PE ratio analysis and historical PE chart
- ASND PS ratio (Price-to-Sales) history and trend
- ASND intrinsic value — DCF, Graham Number, EPV models
- ASND stock price prediction 2025 2026 2027 2028 2029 2030
- ASND fair value vs current price
- ASND insider transactions and insider buying
- Is ASND undervalued or overvalued?
- Ascendis Pharma AS financial analysis — revenue, earnings, cash flow
- ASND Piotroski F-Score and Altman Z-Score
- ASND analyst price target and Smart Rating
Ascendis Pharma AS
📊 No data available
Try selecting a different time range
Smart Analysis
Ascendis Pharma AS (ASND) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Ascendis Pharma AS (ASND) Key Strengths (3)
Revenue surging 42.30% year-over-year
107.39% of shares held by major funds and institutions
Large-cap company with substantial market presence
Supporting Valuation Data
Ascendis Pharma AS (ASND) Areas to Watch (5)
Company is destroying shareholder value
Company is losing money with a negative profit margin
Near-zero operating margins, business under pressure
Very expensive at 18.4x annual revenue
Very expensive at 14.6x book value
Supporting Valuation Data
Ascendis Pharma AS (ASND) Detailed Analysis Report
Overall Assessment
This company scores 30/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 9.7/10) while 5 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own., Market Cap. Growth metrics are encouraging with Revenue Growth at 42.30%.
The Bear Case
The primary concerns are Return on Equity, Profit Margin, Operating Margin. Some valuation metrics including Price/Sales (18.38), Price/Book (14.55) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -818.00%, Operating Margin at 0.96%, Profit Margin at -31.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -818.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 42.30% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ASND Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ASND's Price-to-Sales ratio of 18.38x trades at a deep discount to its historical average of 584.94x (0th percentile). The current valuation is 99% below its historical high of 2847.55x set in Aug 2018, and 0% above its historical low of 18.38x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~26.1x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Ascendis Pharma AS (ASND) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Ascendis Pharma AS is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 720M with 42% growth year-over-year. The company is currently unprofitable, posting a -31.7% profit margin.
Key Findings
Revenue growing at 42% YoY, reaching 720M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Generating 67M in free cash flow and 71M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -31.7% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can Ascendis Pharma AS maintain 42%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Ascendis Pharma AS.
Bottom Line
Ascendis Pharma AS is a high-conviction growth story with revenue accelerating at 42% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -31.7% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Ascendis Pharma AS(ASND)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.